Akebia Therapeutics, Inc.
AKBA$362M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE181 employees
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
AKBA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Erythropoiesis-Stimulating Agent (ESA)
Anemia of Chronic Kidney Disease
Vadadustat
Anemia
Mircera®
Anemia Associated With Chronic Kidney Disease (CKD)
Darbepoetin alfa
Anemia
IW-1973
Heart Failure With Preserved Ejection Fraction
Epoetin Alfa
Anemia
AKB-6548
Anemia
Praliciguat
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Erythropoiesis-Stimulating Agent (ESA) | Phase 3 | Anemia of Chronic Kidney Disease | - | - |
Vadadustat | Phase 3 | Anemia | - | - |
Mircera® | Phase 3 | Anemia Associated With Chronic Kidney Disease (CKD) | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
IW-1973 | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
Epoetin Alfa | Phase 2 | Anemia | - | - |
AKB-6548 | Phase 2 | Anemia | - | - |
Praliciguat | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply